|Articles|August 1, 2004
VisiJet expects quick approval for corneal tissue tool
VisiJet Inc. has filed a 510K statement with the FDA for approval of the Epi-Tome, a next-generation ophthalmic surgical tool designed for cutting and separating corneal tissue.
Advertisement
VisiJet Inc. has filed a 510K statement with the FDA for approval of the Epi-Tome, a next-generation ophthalmic surgical tool designed for cutting and separating corneal tissue.
The company has secured worldwide distribution rights from Gebauer Medizintechnik GmbH of Neuhausen, Germany. The product has earned the CE mark and is being sold in Europe and Korea.
VisiJet expects an expedited FDA approval by fall.OT
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
MeiraGTx Licenses complement-targeted geographic atrophy program from ZipBio
2
Metformin use associated with reduced incidence of intermediate AMD
3
Last year in glaucoma at EnVision Summit 2025
4
Looking back at the 2025 EnVision Summit
5
























